|drug4072||serum NGAL and cystatin c Wiki||1.00|
There is one clinical trial.
Abstract Title: Randomized,open-label, controlled trial to evaluate efficacy and safety of a highly selective semipermeable membrane (AN69-Oxiris) in comparison with a selective semipermeable membrane ( standard AN69) in COVID-19 associated acute kidney injury: oXAKI-COV study Rationale: Acute kidney injury (AKI) in critically ill mechanically ventilated patients with COVID-19 disease, is present in up to 30% of this group and more than 50% of them will need renal replacement therapy in the form of continuous renal replacement therapy (CRRT). Acute kidney injury in this context seems to be a marker of multiorgan dysfunction and it produces increased mortality in this population. There is a vast amount of mechanisms that lead to AKI in critically ill patients with COVID-19; however, the cytokine storm could be the strongest mechanism implicated in AKI development in individuals with continuous renal replacement therapy requirements. Therefore, blocking or reducing the cytokine storm is thought to be a therapeutic target. Highly selective semipermeable membranes (AN69-Oxiris) have been shown able to adsorb endotoxins and to eliminate inflammatory cytokines, thus representing a valuable therapeutic option in this infection. Objective: To demonstrate clinical efficacy of AN69-Oxiris membrane to reach a stable MAP, with less vasopressor dosing (at least 0.1 micrograms/kg/min) after 72h of treatment, compared to a conventional membrane (standard AN69) in critically ill patients with AKI, COVID-19 infection and requirement of continuous renal replacement therapy. Study design: Randomized,open-label, controlled trial in critically ill patients with suspected or confirmed COVID-19 disease, AKI, and criteria for continuous renal replacement therapy initiation admitted in any of the two participating institutions. Patients meeting inclusion criteria will be randomized to receive CRRT with AN69-Oxiris membrane or standard AN69 membrane during a 72h period.
Description: Change in norepinephrine requirement by at least 0.1 micrograms / kg / min to maintain similar MAP after initiation of CRRT with Oxiris membrane compared to standard AN69 membrane. MAP measurements will be performed hourly and norepinephrine requirement will be recorded at that time.Measure: Primary outcome: Time: 90 days
Description: Effectiveness of the AN69-Oxiris membrane in reducing interleukin serum levels (IL 6, IL 10, and TNF alpha). Serum will be taken every 8 hours for its measurement by ELISA method.Measure: Secondary outcomes measures: Time: 72 hours
Description: To establish the safety (the same risk infection and bleeding) of using the AN69- Oxiris membrane in patients with AKI and COVID-19 infection who require CRRT. Gross bleeding events (gastrointestinal or urinary) as well as catheter-associated infection events (criteria according to IDSA) will be recorded.Measure: Secondary outcomes measures: Time: 30 days
Description: Length of stay in UCI among patients who used AN69-Oxiris membrane in compared to the use of a conventional membrane (standard AN-69) in critically ill patients with COVID-19 associated AKI and CRRT requirement.Measure: Secondary outcomes measures: Time: 90 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports